Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge

Virology

Volumn 411, Issue 1, 2011, Pages 87-102

  Patterson, L Jean ^a   Daltabuit Test, Mara ^a   Xiao, Peng ^a   Zhao, Jun ^a   Hu, William ^b   Wille Reece, Ulrike ^c   Brocca Cofano, Egidio ^a   Kalyanaraman, V S ^d   Kalisz, Irene ^d   Whitney, Stephen ^d   Lee, Eun Mi ^d   Pal, Ranajit ^d   Montefiori, David C ^e   Dandekar, Satya ^b   Seder, Robert ^c   Roederer, Mario ^c   Wiseman, Roger W ^f   Hirsch, Vanessa ^g   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF WISCONSIN   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Elite control; Memory; Multifaceted immunity; SIV; Vaccine; Virus sequestration

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUTRALIZING ANTIBODY; TRIPARTITE MOTIF PROTEIN 5; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CARBON SEQUESTRATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DOSE RESPONSE; GENETIC TRANSCRIPTION; GENOTYPE; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; INFECTION CONTROL; INFECTION PREVENTION; INNATE IMMUNITY; MEMORY T LYMPHOCYTE; MICROARRAY ANALYSIS; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROTEIN INDUCTION; PROVOCATION TEST; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS ENVELOPE; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REACTIVATION; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; JEJUNUM; LYMPH NODES; MACACA MULATTA; SERUM; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VIREMIA;

ANIMALIA; MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 79551680473     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.12.033     Document Type: Article

References (54)

1. Baker B.M., Block B.L., Rothchild A.C., Walker B.D. Elite control of HIV infection: implications for vaccine design. Expert Opin. Biol. Ther. 2009, 9:55-69.
2. Bertley F.M., Kozlowski P.A., Wang S.-W., Chappelle J., Patel J., Sonuyi O., Mazzara G., Montefiori D., Carville A., Mansfield K.G., Aldovini A. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J. Immunol. 2004, 172:3745-3757.
3. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 1997, 3:42-47.
4. Bosinger S.E., Li Q., Gordon S.N., Klatt N.R., Duan L., Xu L., Francella N., Sidahmed A., Smith A.J., Cramer E.M., Zeng M., Masopust D., Carlis J.V., Ran L., Vanderford T.H., Paiardini M., Isett R.B., Baldwin D.A., Else J.G., Staprans S.I., Silvestri G., Haase A.T., Kelvin D.J. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J. Clin. Invest. 2009, 119:3556-3572.
5. Bostik P., Kobkitjaroen J., Tang W., Villinger F., Pereira L.E., Little D.M., Stephenson S.T., Bouzyk B., Ansari A.A. Decreased NK cell frequency and function is associated with increased risk of KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhesus macaques with high viral loads. J. Immunol. 2009, 182:3638-3649.
6. Buge S.L., Richardson E., Alipanah S., Markham P., Cheng S., Kalyan N., Miller C.J., Lubeck M., Udem S., Eldridge J., Robert-Guroff M. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 1997, 71:8531-8541.
7. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W.B., Davey D.F., Flynn B.J., Hoff S.T., Andersen P., Reed S.G., Morris S.L., Roederer M., Seder R.A. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 2007, 13:843-850.
8. Decker J.M., Bibollet-Ruche F., Wei X., Wang S., Levy D.N., Wang W., Delaporte E., Peeters M., Derdeyn C.A., Allen S., Hunter E., Saag M.S., Hoxie J.A., Hahn B.H., Dwong P.D., Robinson J.E., Shaw G.M. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 2005, 201:1407-1419.
9. Deeks S.G., Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27:406-416.
10. Devito C., Broliden K., Kaul R., Svensson L., Johansen K., Kiama P., Kimani J., Lopalco L., Piconi S., Bwayo J.J., Plummer F., Clerici M., Hinkula J. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 2000, 165:5170-5176.
11. Ferre A.L., Hunt P.W., Critchfield J.W., Young D.H., Morris M.M., Garcia J.C., Pollard R.B., Yee H.F., Martin J.N., Deeks S.G., Shacklett B.L. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009, 113:3978-3989.
12. Florese R.H., Demberg T., Xiao P., Kuller L., Larsen K., Summers L.E., Venzon D., Cafaro A., Ensoli B., Robert-Guroff M. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J. Immunol. 2009, 182:3718-3727.
13. Forthal D.N., Landucci G., Cole K.S., Marthas M., Becerra J.C., Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J. Virol. 2006, 80:9217-9225.
14. Friedrich T.C., Valentine L.E., Yant L.J., Rakasz E.G., Piaskowski S.M., Furlott J.R., Weisgrau K.L., Burwitz B., May G.E., Leon E.J., Soma T., Napoe G., Capuano S.V., Wilson N.A., Watkins D.I. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J. Virol. 2007, 81:3465-3476.
15. Genesca M., Skinner P.J., Bost K.M., Lu D., Wang Y., Rourke T.L., Haase A.T., McChesney M.B., Miller C.J. Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol. 2008, 1:219-228.
16. George M.D., Sankaran S., Reay E., Gelli A.C., Dandekar S. High-throughput gene expression profiling indicates dysregulation of intestinal cell cycle mediators and growth factors during primary simian immunodeficiency virus infection. Virology 2003, 312:84-94.
17. George M.D., Reay E., Sankaran S., Dandekar S. Early antiretrovial therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J. Virol. 2005, 79:2709-2719.
18. *0306 are enriched in a cohort of simian immunodeficiency virus-infected rhesus macaque elite controllers. J. Virol. 2008, 82:859-870.
19. Gomez-Roman V.R., Patterson L.J., Venzon D., Liewehr D., Aldrich K., Florese R., Robert-Guroff M. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 2005, 174:2185-2189.
20. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., Piatak M., Lifson J.D., Nelson J.A., Jarvis M.A., Picker L.J. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 2009, 15:293-299.
21. Hidajat R., Xiao P., Zhou Q., Venzon D., Summers L.E., Kalyanaraman V.S., Montefiori D.C., Robert-Guroff M. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol. 2009, 83:791-801.
22. Hirsch V.M., Johnson P.R. Pathogenic diversity of simian immunodeficiency viruses. Virus Res. 1994, 32:183-203.
23. Kirmaier, A., Wu, F., Newman, R.M., Hall, L.R., Morgan, J.S., O'Conner, S., Marx, P.A., Meythaler, M., Goldstein, S., Buckler-White, A., Kaur, A., Hirsch, V.M., Johnson, W.E., 2010. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol. 8 (8), e1000462.
24. Lambotte O., Ferrari G., Moog C., Yates N.L., Liao H.-X., Parks R.J., Hicks C.B., Owzar K., Tomaras G.D., Montefiori D.C., Haynes B.F., Delfraissy J.-F. Heterologous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009, 23:897-906.
25. Lee E.M., Chung H.K., Livesay J., Suschak J., Fink L., Hudacik L., Galmin L., Bowen B., Markham P., Cristillo A., Pal R. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J. Virol. Methods 2010, 163:287-294.
26. Leutenegger C.M., Higgins J., Matthews T.B., Tarantal A.F., Luciw P.A., Pedersen N.C., North T.W. Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Res. Hum. Retro. 2001, 17:243-251.
27. Li Q., Duan L., Estes J.D., Ma Z.-M., Rourke T., Wang Y., Reilly C., Carlis J., Miller C.J., Haase A.T. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434:1148-1152.
28. Li Q., Skinner P.J., Ha S.-J., Duan L., Mattila T.L., Hage A., White C., Barber D.L., O'Mara L., Southern P.J., Reilly C.S., Carlis J.V., Miller C.J., Ahmed R., Haase A.T. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 2009, 323:1726-1729.
29. Lim S.-Y., Rogers T., Whitney J.B., Kim J., Sodroski J., Letvin N.L. TRIM5α modulates immunodeficiency virus control in rhesus monkeys. PLoS Pathog. 2010, 6(1):e1000738. 10.1371/journal.ppat.1000738.
30. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., Rosenkrands I., Andersen P. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 2009, 182:8047-8055.
31. *08-positive macaques control simian immunodeficiency virus replication. J. Virol. 2007, 81:8827-8832.
32. Malkevitch N.V., Patterson L.J., Aldrich M.K., Wu Y., Venzon D., Florese R.H., Kalyanaraman V.S., Pal R., Lee E.M., Zhao J., Cristillo A., Robert-Guroff M. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 2006, 353:83-98.
33. Manrique M., Kozlowski P.A., Wang S.-W., Wilson R.L., Micewicz E., Montefiori D.C., Mansfield K.G., Carville A., Aldovini A. Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Muc. Immunol. 2009, 2:536-550.
34. Miller C.J., Li Q., Abel K., Kim E.-Y., Ma Z.-M., Wietgrefe S., Franco-Scheuch L.L., Compton L., Duan L., Shore M.D., Zupancic M., Busch M., Carlis J., Wolinsky S., Haase A.T. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 2005, 79:9217-9227.
35. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Current Protocols in Immunology 2004, 12.11.1-12.11.15. John Wiley & Sons. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, R. Coico (Eds.).
36. North T.W., Higgins J., Deere J.D., Hayes T.L., Villalobos A., Adamson L., Shacklett B.L., Schinazi R.F., Luciw P.A. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J. Virol. 2010, 84:2913-2922.
37. O'Connell K.A., Han Y., Williams T.M., Siliciano R.F., Blankson J.N. Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J. Virol. 2009, 83:5028-5034.
38. O'Connell K.A., Brennan T.P., Bailey J.R., Ray S.C., Siliciano R.F., Blankson J.N. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J. Virol. 2010, 84:7018-7028.
39. *01) delay simian immunodeficiency virus SIV-mac-induced immunodeficiency. J. Virol. 2002, 76:292-302.
40. Patterson L.J., Malkevitch N., Pinczweski J., Venzon D., Lou Y., Peng B., Munch C., Leonard M., Richardson E., Aldrich K., Kalyanaraman V.S., Pavlakis G.N., Robert-Guroff M. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J. Virol. 2003, 77:8607-8620.
41. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., Kalyanaraman V.S., Markham P.D., Robey F.A., Robert-Guroff M. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J. Virol. 2004, 78:2212-2221.
42. *01 negative rhesus macaques. Virology 2008, 374:322-337.
43. Pereyra F., Palmer S., Miura T., Block B.L., Wiegand A., Rothchild A.C., Baker B., Rosenberg R., Cutrell E., Seaman M.S., Coffin J.M., Walker B.D. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis. 2009, 200:984-990.
44. Prado J.G., Prendergast A., Thobakgale C., Molina C., Tudor-Williams G., Ndung'u T., Walker B.D., Goulder P. Replicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rate. J. Virol. 2010, 84:492-502.
45. Romano J.W., Shurtliff R.N., Dobratz E., Gibson A., Hickman K., Markham P.D., Pal R. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J. Virol. Methods 2000, 86:61-70.
46. Sacha J.B., Giraldo-Vela J.P., Buechler M.B., Martins M.A., Maness N.J., Chung C., Wallace L.T., Leon E.J., Friedrich T.C., Wilson N.A., Hiraoka A., Watkins D.I. Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. PNAS 2009, 106:9791-9796.
47. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 2008, 8:247-258.
48. Shen R., Drelichman E.R., Bimczok D., Ochsenbauer C., Kappes J.C., Cannon J.A., Tudor D., Bomsel M., Smythies L.E., Smith P.D. Gp41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J. Immunol. 2010, 184:3648-3655.
49. *08-positive macaques. J. Virol. 2009, 83:11514-11527.
50. Wiseman R.W., Karl J.A., Bimber B.N., O'Leary C.E., Lank S.M., Tuscher J.J., Detmer A.M., Bouffard P., Levenkova N., Turcotte C.L., Szekeres E., Wright C., Harkins T., O'Conner D.H. Major histocompatibility complex genotyping with massively parallel pyrosequencing. Nat. Med. 2009, 15:1322-1327.
51. Xiao P., Zhao J., Patterson L.J., Brocca-Cofano E., Venzon D., Kozlowski P.A., Hidajat R., Demberg T., Robert-Guroff M. Multiple vaccine-elicited non-neutralizing anti-envelope antibody activities contribute to protective efficacy against SHIV89.6P challenge in rhesus macaques. J. Virol. 2010, 84:7161-7173.
52. *17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 2006, 80:5074-5077.
53. Yeh W.W., Jaru-ampornpan P., Nevidomskyte D., Asmal M., Rao S.S., Buzby A.P., Montefiori D.C., Korber B.T., Letvin N.L. Partial protection of simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J. Virol. 2009, 83:2686-2696.
54. *01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J. Virol. 2002, 76:12845-12854.